|
|
411 Hackensack Avenue
Hackensack, NJ 07601 USA
phone:(+1) 201.651.5140
fax:+1-201-6515141
|
|
| Symbol |
RGBO |
| Exchange |
OTC |
| Founded |
1990 |
| Employees |
|
|
|
| www.regenbio.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Meniscus cartilage repair. |
|
| Management |
| Gerald E. Bisbee, Jr., Ph.D., Chairman, President and CEO; John Dichiara, Senior Vice President, Clinical and Regulatory Affairs; William G. Rodkey, DVM, Vice President, Scientific Affairs; Brion D. Umidi, Senior Vice President and Chief Financial Officer |
| |
|
|
|
|
|
|
|
| Keywords |
| reconstruction, orthopedics, advamed |
|
|
|
| Description |
|
ReGen Biologics develops tissue repair products for U.S. and global markets. The company's collagen scaffold technology includes applications in orthopedics, general surgery, spine, cardiovascular and drug delivery. ReGen's initial focus is on the knee; the company's first approved product is the CMI, a resorbable type I collagen scaffold sutured to the remaining meniscus following a partial meniscectomy. The device is designed to reinforce the remaining tissue and provide a scaffold for the growth of new tissue to replace what was removed in the partial meniscectomy procedure. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
